We already knew it was happening. Now there's data to show us how pervasive it is. A large-scale physician and chemist census across India's top 120 cities and towns by Mumbai-based market research and consultancy firm IMS Health has found that non-M.B.B.S doctors i.e. doctors who don't hold a degree in medicine accounted for 16 … Continue reading Who’s treating you? New data shows extent of non-MBBS docs practising allopathy in India
On December 7, India's National Pharmaceutical Pricing Policy 2012 was finally tabled in Parliament. Assuming that this policy does get rolled out irrespective of a Supreme Court hearing on drug pricing playing out in parallel, the cornerstone of the policy i.e.data may create some vexing issues. The Policy envisages fixing ceiling prices of specified strengths … Continue reading India’s new drug pricing policy : will data be the stumbling block?
Could a single word in the new drug pricing policy mitigate the extent of its impact on the pharma industry's profitability or is this mere wishful thinking? A senior industry source claimed to Apothecurry that the choice of "value" instead of "volume" as a determinant of market share (on the basis of which prices will … Continue reading India & drug pricing : Can key word in policy influence impact?
At a recent press conference to announce the launch of its vaccine Prevenar 13, Pfizer MD Kewal Handa declined to share revenue numbers of the vaccine's predecessor Prevenar in India. That's not surprising - companies rarely reveal internal numbers for specific products. But what was surprising is that it did not provide ORG-IMS numbers either. The … Continue reading No Indian data on vaccines market?